1-5 of 5
Carmen D. Schweighofer, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk Binet Stage A Chronic Lymphocytic Leukemia – First Results Of a Randomized German-French Cooperative Phase III Trial

Carmen D Schweighofer, MD, Florence Cymbalista, MD, Carolin Müller, MD, Raymonde Busch, PhD, Raphael Porcher, PhD, Petra Langerbeins, MD, Bruno Cazin, MD, Anna-Maria Fink, MD, Brigitte Dreyfus, MD, Stefan Ibach, Stéphane Leprêtre, MD, Kirsten Fischer, MD, Ursula Vehling-Kaiser, MD, Barbara Eichhorst, MD, Manuela A. Bergmann, MD, Stephan Stilgenbauer, MD, Hartmut Döhner, MD, Veronique Leblond, MD, Michael Hallek, MD, Vincent Levy, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 524.
https://doi.org/10.1182/blood.V122.21.524.524
Published: 2013
Journal Articles

Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG)

Kirsten Fischer, MD, Stephan Stilgenbauer, MD, Carmen D Schweighofer, MD, Raymonde Busch, Jasmin Renschler, Michael Kiehl, MD, Leopold Balleisen, MD, Michael J Eckart, MD, Anna- Maria Fink, MD, Julia Kilp, MD, Matthias Ritgen, MD, Sebastian Böttcher, MD, Michael Kneba, MD, PhD, Hartmut Döhner, MD, Barbara F Eichhorst, MD, Michael Hallek, MD, Clemens- Martin Wendtner, MD, The German CLL Study Group
Journal: Blood
Blood (2008) 112 (11): 330.
https://doi.org/10.1182/blood.V112.11.330.330
Published: 2008
Journal Articles

Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG).

Kirsten Fischer, MD, Stephan Stilgenbauer, MD, Carmen D. Schweighofer, MD, Jasmin Renschler, Raymonde Busch, Michael Kiehl, MD, Leopold Balleisen, MD, Michael Eckart, MD, Anna M. Fink, MD, Sebastian Boettcher, MD, Matthias Ritgen, MD, Michael Kneba, MD, Peter Staib, MD, Hartmut Doehner, MD, Barbara F. Eichhorst, MD, Michael Hallek, MD, Clemens-Martin Wendtner, MD, the German CLL Study Group (GCLLSG)
Journal: Blood
Blood (2007) 110 (11): 3106.
https://doi.org/10.1182/blood.V110.11.3106.3106
Published: 2007
Journal Articles

Dose Escalation Study To Evaluate Dose Limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and Safety of Alemtuzumab for Consolidation Therapy in Patients with Chronic Lymphoycytic Leukemia: Phase I/II Trial of the German CLL Study Group (GCLLSG).

Kirsten Fischer, MD, Carmen D. Schweighofer, MD, Matthias Ritgen, MD, Sebastian Boettcher, MD, Elena Scharf, Barbara F. Eichhorst, MD, Raymonde Busch, Wolfgang Abenhardt, MD, Michael Kneba, MD, Michael Hallek, MD, Clemens-Martin Wendtner, MD, the German CLL Study Group (GCLLSG)
Journal: Blood
Blood (2007) 110 (11): 2053.
https://doi.org/10.1182/blood.V110.11.2053.2053
Published: 2007
Journal Articles

No Significant Clinical Benefit of First Line Therapy with Fludarabine (F) in Comparison to Chlorambucil (Clb) in Elderly Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Phase III Study of the German CLL Study Group (GCLLSG).

Barbara F. Eichhorst, MD, Raymonde Busch, Martina Stauch, MD, Manuela Bergmann, MD, Matthias Ritgen, MD, Nicole Kranzhöfer, MD, Carmen D. Schweighofer, MD, Kirsten Fischer, MD, Anna-Maria Fink, MD, Paula Cramer, Valentin Goede, MD, Clemens M. Wendtner, MD, Michael Hallek, MD, GCLLSG
Journal: Blood
Blood (2007) 110 (11): 629.
https://doi.org/10.1182/blood.V110.11.629.629
Published: 2007